Vancouver, BC – Novelogics Biotechnology, Inc. announced today that it has entered into a research agreement with The Centre for Drug Research and Development (CDRD), Canada’s national drug development and commercialization centre, to further characterize Novelogics’ internally-developed antibody immunotherapy for treating cancer.
The proprietary technology behind Novelogics’ innovation involves discovery and development of monoclonal antibodies that target a protein that promotes immune suppression in cancer patients. It is predicted that this new therapy could treat a broad range of cancers, and because it works with the patient’s own immune system, it would be safer and less toxic with fewer debilitating side-effects.
CDRD will be analyzing the technology through custom in vitro assays that will help validate and identify their lead antibody and move it towards a Phase 1 clinical trial as early as 2019. The technology has recently shown preliminary evidence of tumour inhibition in a prostate cancer model and based on results from CDRD’s research, it could be expanded to other cancer models.
Novelogics’ President and Chief Scientific Officer Dr. Wayne Cheney stated, “We are excited to introduce our novel approach to treating cancer. Unlike other immunotherapies that function by modulating, inhibiting or blocking targets, our innovative drug works by intercepting. This is a new way of limiting the immune suppressive effects of the drug target, which offers a huge opportunity to make a difference in the fight against cancer. We look forward to a successful collaboration with CDRD and are thrilled to be working with their technical team of experts and state-of-the-art biologics facility.”
CDRD’s Head of Biologics Dr. Ismael Samudio commented, “This work with Novelogics is an exciting opportunity for CDRD to apply our scientific expertise in NK cell biology and therapeutic antibodies to a technology that has very promising pre-clinical potential. This a great example of how CDRD is partnering with Canadian life sciences companies to advance promising discoveries and transform them into validated investments and improved health outcomes. By combining our expertise and specialized infrastructure, we aim to provide critical data to advance Novelogics’ technology and help bring new therapeutic treatments to market.”
It is anticipated that a pre-clinical candidate antibody will be selected in 2017, and that further clinical development activities will follow.
– 30 –
About Novelogics Biotechnology, Inc.
Novelogics Biotechnology Inc. is virtual life sciences company utilizing expertise at a variety of Contract Research labs and is dedicated to developing innovative cancer treatments that harness the power of the immune system to help eradicate tumors more naturally. Their immunotherapy concepts focus on development of antibody therapeutics and have the potential to treat multiple cancer types without the side-effects associated with traditional cancer therapies. We anticipate the technology will be well-received by larger biotechnology and pharmaceutical companies seeking novel antibody immunotherapy treatments in this exciting area of cancer drug development. Novelogics has one mission in mind – we want to create better cancer treatments. www.novelogics.com
About The Centre for Drug Research and Development (CDRD)
CDRD is Canada’s national drug development and commercialization centre working in partnership with academia, industry, government and foundations. CDRD provides the specialized expertise and infrastructure to identify, validate and advance promising discoveries, and transform them into commercially viable investment opportunities for the private sector — and ultimately into new therapies for patients. Canada’s Networks of Centres of Excellence Program has recognized CDRD as a Centre of Excellence for Commercialization and Research (CECR). www.cdrd.ca
Phone: (604) 723-7774
Manager, Communications – CDRD
Phone: (604) 827-1226